3 results about "Seroconversion" patented technology

This invention provides a composite adjuvant, its preparation method, and its application in vaccine preparation, belonging to the field of vaccine adjuvant technology. The composite adjuvant of this invention has low viscosity, only 12 mPa·s at 20°C, ensuring smooth injection; it exhibits high biocompatibility, with no deaths or organ abnormalities in acute toxicity experiments in mice, and no local or systemic adverse reactions or stress responses in chickens after injection; it also demonstrates excellent immunogenicity, achieving a 90% seroconversion rate for Mycoplasma cambogia and an 80% seroconversion rate for Mycoplasma synoviae 28 days after immunization with an inactivated Mycoplasma synoviae vaccine.

The present application relates to the technical field of biological medicine, and particularly relates to a fusion protein and application thereof in preparation of a product for treating or preventing hepatitis B virus. The present application takes preS1 as a core antigen component and takes an improved IgM as a basic skeleton to obtain a preS1-IgM monomer, and then connects the preS1-IgM monomer through a J chain to obtain a fusion protein. The fusion protein is taken as an active component to construct a therapeutic vaccine, which can effectively stimulate an anti-preS1 antibody response and synergistically activate a Th1 / Th2 immune response. Experiments show that the vaccine alone can significantly reduce the serum HBsAg, HBV DNA and intrahepatic virus antigen levels of a chronic HBV infection model, and realize seroconversion of part of the animals. When the vaccine is used in combination with entecavir, a remarkable synergistic effect is exhibited. The vaccine significantly improves the therapeutic effect without causing significant liver damage, and provides an innovative immunotherapy with both prevention and treatment functions for chronic hepatitis B treatment.

The present invention relates to the technical field of vaccine preparation, and particularly, to a bivalent inactivated EV71-CA16 vaccine, a method for preparing the same, and use thereof. The present invention implements the preparation by means of separately adsorbing a monovalent viral stock solution containing an EV71 antigen and a monovalent viral stock solution containing a CA16 antigen with an adjuvant and then mixing same, thereby improving the content of the EV71 antigen and the CA16 antigen in the vaccine substance and greatly improving the adsorption rate and recovery rate of EV71 and CA16 antigens. Moreover, the bivalent EV71-CA16 viral antigen can cause positive seroconversion and up-regulation of the corresponding neutralizing antibody and induce a higher serum antibody level, thus facilitating the preparation of the bivalent inactivated EV71-CA16 vaccine and preventing hand-foot-and-mouth disease.